- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04497285
Real World Study Using Comprehensive Genomic Data on the Next Treatment Decision Making in Metastatic Breast Cancer (HOPE)
HOPE: Real World Clinical Practice Study to Assess the Impact of Using Comprehensive Genomic Data on the Next Treatment Decision Making Choice in Patients With Locally Advanced or Metastatic Breast Cancer in Spain
SOLTI 1903 HOPE is a national, real world clinical practice study conducted in patients diagnosed with metastatic breast cancer who are receiving, have just received or will receive treatment for its advanced disease. Patients will lead their inclusion, participation and follow-up in the study through a digital tool, but they are encouraged to include their physician's in this study. Tissue samples from metastatic (preferred) or primary tumor will be collected for analyses, together with blood samples. A Molecular Advisory Board (MAB) will assess and give recommendations according patient's molecular profile.
The primary objective is to assess the real-world clinical practice of integration of molecular profiling in the Standard of Care (SoC) management of mBC patients connected through a digital tool.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Eligible patients are those who are 18 or older, either female or male, confirmed locally advanced or metastatic breast cancer of any subtype and who have received, are receiving, or will receive any line of treatment from metastatic disease.
Demographic data, disease characteristics, treatment history, and quality of life data will be collected through a digital tool by the patient. The data are de-identified and will be used to advance multiple areas of research into mBC. The study will be complemented by a patient empowerment program that will include informative workshops and video-tutorials about precision medicine and the HOPE study itself. Tumor tissue samples must be submitted for genomic profiling using FoundationOne CDx. Blood samples for circulating tumor DNA (ctDNA) profiling using Guardant360 also will be collected.
Molecular reports will be reviewed by the Molecular Advisory Board (MAB) and recommendations according to the molecular profile will be sent to the patients and physicians through the digital tool to let them know these treatment options and also notified about clinical trials for which they may be eligible.
The primary objective is to assess the real-world clinical practice of integration of molecular profiling in the Standard of Care (SoC) management of mBC patients connected through a digital tool. Secondary objectives include: to describe genetic mutational profile from both tests, to evaluate if a patient-centric strategy could achieve better enrollment than the classical approach site-physician-patient, and to assess the efficacy of the program to allocate patients in clinical trials.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Please Select
-
Barcelona, Please Select, Spain, 08008
- Translational Genomics and Targeted Therapeutics in Solid Tumours Lab in August Pi i Sunyer Biomedical Research Institute (IDIBAPS)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Female or Male patients.
- Age ≥18 years.
- Signed informed consent prior to any screening procedure.
- Locally advanced or metastatic breast cancer of any subtype confirmed both pathologically and radiologically (stage IIIb- IV disease).
- The subjects must be about to receive, or receiving, or will have completed treatment for their metastatic disease with any line of treatment in either a clinical trial or the healthcare setting.
- Availability of one metastatic (preferably), primary tumor sample or blood sample.
- Measurable or non-measurable disease.
- Quality of life score according to ECOG scale ≤ 3.
- Minimal life expectancy of 6 months.
Exclusion Criteria:
- Inability to consent or conform to the processes involved in a clinical study.
- Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Metastatic breast cancer management based on tumor molecular profile
Time Frame: 1 year after end of accrual
|
The number of patients assigned to different treatments based on the genomic profile.
|
1 year after end of accrual
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Description of the genetic mutational profile in tumor tissue.
Time Frame: Ongoing basis during 3 years' patient recruitment
|
To describe the genetic mutational profile of the patients using Foundation One CDx.
|
Ongoing basis during 3 years' patient recruitment
|
Description of the genetic mutational profile in blood samples
Time Frame: Ongoing basis during 3 years' patient recruitment
|
To describe the genetic mutational profile of the patients using liquid biopsy (Guardant360 test).
|
Ongoing basis during 3 years' patient recruitment
|
Description of the enrollment rate of the study
Time Frame: Ongoing basis during 3 years' patient recruitment
|
To describe the enrollment rate using the HOPE patient centric strategy (videotutorials and user experience of different technologies as the digital tool).
|
Ongoing basis during 3 years' patient recruitment
|
Feasibility of implementing the program for metastatic breast cancer
Time Frame: 1 year after end of accrual and subsequently during follow up period of 5 years
|
To describe number of patients who are allocated to clinical trials and number of patients allocated on on-label therapies considering tumor genomic profile.
|
1 year after end of accrual and subsequently during follow up period of 5 years
|
Correlation between efficacy endpoints among patients enrolled in clinical trials according to the tumor's genomic profile and among patients receiving SoC.
Time Frame: 1 year after end of accrual and subsequently during follow up period of 5 years
|
To describe of PFS and OS among the patients enrolled in clinical trials according to the tumor's genomic profile, and among the patients receiving SoC.
|
1 year after end of accrual and subsequently during follow up period of 5 years
|
Quality of life assessment using EuroQol-5D (EQ-5D) in patients with metastatic breast cancer
Time Frame: Ongoing basis during 3 years' patient recruitment
|
The EuroQol EQ-5D is designed to assess health status in terms of a single index value or utility score.
It contains 5 descriptors of current health state (mobility, self-care, usual activities, pain or discomfort, and anxiety or depression) with each dimension having 5 levels of function (1=no problem, 2=slight problem, 3=moderate problem, 4=severe problem, and 5=unable/extreme).
The scores on the 5 descriptors are summarized to create a single summary score.
The EQ-5D also includes a visual analog scale (VAS), in which the patients self-rate their overall health status on a scale from 0 (worst imaginable) to 100 (best imaginable).
|
Ongoing basis during 3 years' patient recruitment
|
Quality of life assessment using Functional Assessment of Cancer Therapy FACT-B in patients with metastatic breast cancer
Time Frame: Ongoing basis during 3 years' patient recruitment
|
The FACT-B consists of the Functional Assessment of Cancer Therapy-General (FACT-G) (27-items) and a breast-specific module: a 10-item instrument designed to assess patient concernsrelating to BC.
The FACT-G is a 27-item compilation of general questions divided into 4 domains: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, and Functional Well-Being.
Patients are asked to respond to a Likert scale where 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, and 4=very much.
|
Ongoing basis during 3 years' patient recruitment
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SOLTI-1903
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Breast Cancer
-
Gilead SciencesRecruitingStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast CancerJapan
-
BriaCell Therapeutics CorporationRecruitingBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer Metastatic | End Stage CancerUnited States
-
GlycoMimetics IncorporatedTerminatedBreast Cancer | Breast Cancer Metastatic | HR+ Metastatic Breast CancerUnited States
-
OBI Pharma, IncCompletedMetastatic Colorectal Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric CancerTaiwan
-
Massachusetts General HospitalPuma Biotechnology, Inc.; Celcuity, Inc.WithdrawnMetastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer | Stage IV (Metastatic) Breast CancerUnited States
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | Postmenopausal Women | Locally Advanced Metastatic Breast CancerIsrael
-
BriaCell Therapeutics CorporationLumaBridgeEnrolling by invitationBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer MetastaticUnited States
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedMetastatic Breast Cancer | Metastatic Triple Negative Breast CancerJapan, Belgium, France, Netherlands
-
Prof. Wolfgang JanniEli Lilly and CompanyRecruitingHormone Receptor-positive Metastatic Breast Cancer | HER2-negative Metastatic Breast CancerGermany
-
Hoffmann-La RocheCompletedHER2-Positive Metastatic Breast Cancer | HER2-Negative Metastatic Breast Cancer | Locally Advanced or Early Breast CancerUnited States
Clinical Trials on blood sample collection and collection of tumor tissue block
-
Centre Hospitalier Universitaire de BesanconRecruiting
-
Merck Sharp & Dohme LLCRecruitingCarcinoma, Non-Small-Cell LungPoland, United States, Hungary, Israel, Italy, Korea, Republic of, Spain
-
Thomas Jefferson UniversityRecruitingBreast Cancer | Invasive Breast Cancer | Carcinoma in Situ of the BreastUnited States
-
University Health Network, TorontoRecruiting
-
H. Lee Moffitt Cancer Center and Research InstituteActive, not recruitingPancreatic Cancer | Cancer CachexiaUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteNational Cancer Institute (NCI); University of Miami; University of FloridaRecruitingPancreatic Cancer | Pancreatic CystUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteUnited States Department of DefenseActive, not recruitingPancreatic CancerUnited States
-
University Hospital, AngersRecruitingDevelopment Delay | Cancer Childhood | Predisposition, GeneticFrance, Réunion
-
University Health Network, TorontoWithdrawnBiliary Tract Cancer